Bile Duct Injury due to Drug Induced Liver Injury.
Cholangitis
Drug-induced liver injury (DILI)
Journal
Current hepatology reports
ISSN: 2195-9595
Titre abrégé: Curr Hepatol Rep
Pays: United States
ID NLM: 101631871
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
2
11
2020
pubmed:
1
1
2019
medline:
1
1
2019
Statut:
ppublish
Résumé
Drug-induced liver injury (DILI) can present with a variable clinical and pathological phenotype and can be classified using liver enzymes as hepatocellular, cholestatic or a mixed pattern. The cholestatic pattern has been considered amongst the spectrum of direct liver damage at the microscopic level, but recently bile duct injury as a manifestation of DILI has emerged as a distinct entity and this review examines several examples of biliary tract abnormalities due to DILI from a clinical, radiologic and pathologic perspective. Case series and reports have emerged over the last few years of drugs causing cholangiographic changes or direct injury to the intra-and extra-hepatic biliary tree, such as ketamine and several chemotherapy agents. The DILI Network (DILIN) in the United States has published their experience of cases with vanishing bile duct syndrome on histology and sclerosing cholangitis like changes seen on cholangiography. The pathogenesis of these changes is unclear but it appears that this type of injury is more severe and more likely to lead to a chronic injury with increased mortality than other cases of DILI. Bile duct injury due to DILI is an increasingly recognized entity and imaging of the biliary tree in conjunction with liver biopsy should be considered in patients with severe cholestatic DILI.
Identifiants
pubmed: 33134030
doi: 10.1007/s11901-019-00474-0
pmc: PMC7597665
mid: NIHMS1534652
doi:
Types de publication
Journal Article
Langues
eng
Pagination
269-273Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK100928
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest Priya Grewal and Jawad Ahmad each declare no potential conflicts of interest.
Références
Am J Gastroenterol. 2011 May;106(5):1004-5
pubmed: 21540907
Clin Gastroenterol Hepatol. 2014 Oct;12(10):1759-62.e1
pubmed: 24534547
Clin Gastroenterol Hepatol. 2019 Mar;17(4):789-790
pubmed: 29966706
Gastroenterology. 2015 Jun;148(7):1340-52.e7
pubmed: 25754159
Gastroenterology. 2010 Jun;138(7):2246-59
pubmed: 20394749
Hepatology. 2013 Aug;58(2):825-7
pubmed: 23695896
J Pediatr Gastroenterol Nutr. 2013 Nov;57(5):e30-1
pubmed: 23969539
Am J Gastroenterol. 1996 Jul;91(7):1456-7
pubmed: 8678017
J Hepatol. 1990 May;10(3):341-5
pubmed: 1973179
J Am Coll Radiol. 2013 Jun;10(6):402-9
pubmed: 23632132
Hepatology. 2014 Feb;59(2):661-70
pubmed: 24037963
Aliment Pharmacol Ther. 2010 Jul;32(1):3-13
pubmed: 20374223
Hepatology. 1999 Dec;30(6):1498-506
pubmed: 10573530
J Hepatol. 2018 Jul;69(1):121-128
pubmed: 29551711
Dig Liver Dis. 2015 Jun;47(6):502-7
pubmed: 25840876
Dig Dis Sci. 2015 Dec;60(12):3814-6
pubmed: 26501143
Am J Gastroenterol. 2017 Jan;112(1):18-35
pubmed: 27995906
Hepatology. 2017 Apr;65(4):1267-1277
pubmed: 27981596
Clin Radiol. 2005 Jun;60(6):700-9
pubmed: 16038698
World J Gastroenterol. 2007 Dec 7;13(45):6087-9
pubmed: 18023105
Clin Radiol. 2006 Aug;61(8):670-8
pubmed: 16843750